Advertisement

CNS Drugs

, Volume 15, Issue 5, pp 391–411 | Cite as

Smoking Cessation in Women

Special Considerations
  • Kenneth A. PerkinsEmail author
Review Article

Abstract

Women may be at relatively greater risk of smoking-related diseases than men but tend to have less success than men in quitting smoking. The failure of most outcome studies to report results by gender and the lack of statistical power for detecting significant gender differences currently do not allow for many firm conclusions to be drawn about smoking cessation rates in women, but several trends warrant attention and further study.

First, the difference in cessation rates for women versus men may be even greater in trials of nicotine replacement therapies (NRT). This suggests that women benefit less from NRT relative to men, although this difference may depend on the particular form of NRT (e.g. inhaler versus gum). On the other hand, some non-NRT medications may reverse the poorer outcome of women, producing quit rates in women comparable with those in men. Gender differences in outcome, as well as overall success rates, with NRT and some of the non-NRT medications appear to be enhanced when treatment includes substantial behavioural counselling. However, while several of the non-NRT medications may be particularly appropriate to consider for treating women trying to quit smoking, adverse effects may limit widespread use of some of these drugs, such as clonidine and naltrexone. Thus, even if the gender differences in outcome with NRT versus non-NRT drugs are confirmed in further research, such findings do not necessarily justify limiting NRT use in women, because such treatment is clearly effective and is likely to be safer and more readily available than non-NRT medications. Nevertheless, study of the mechanisms by which some non-NRT drugs are effective in women may aid our understanding of factors that are more influential in smoking behaviour in women than in men.

Secondly, smoking cessation treatment for women must address several other issues that often emerge, and these are most likely to require behavioural counselling that is tailored to these problems. These issues include concern about bodyweight gain, restrictions on medication use in pregnant smokers, variability in mood and withdrawal as a function of menstrual cycle phase, harnessing social support to foster abstinence, and the possibility that smoking-associated environmental cues may be more influential in smoking behaviour in women than men.

Greater attention to gender differences in clinical trial outcomes and to addressing concerns of women smokers may aid in the development of substantially improved smoking cessation interventions for women.

Keywords

Nicotine Smoking Cessation Clonidine Naltrexone Nicotine Replacement Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

Dr Perkins has received honoraria for educational activities from Glaxo Wellcome and has provided consultation services to Elan Pharmaceuticals, Pfizer, and Murty Pharmaceuticals. No support for the preparation of this manuscript was received from these sponsors. Preparation of this manuscript was supported by Grants DA04174 and DA12655 from the National Institute on Drug Abuse of the U.S. Public Health Service.

References

  1. 1.
    Peto R, Lopez AD, Boreham J, et al. Mortality from smoking worldwide. Br Med Bull 1996; 52: 12–21PubMedCrossRefGoogle Scholar
  2. 2.
    Amos A. Women and smoking. Br Med Bull 1996; 52: 74–89PubMedCrossRefGoogle Scholar
  3. 3.
    Lopez AD, Collishaw NE, Piha T. A descriptive model of the cigarette epidemic in developed countries. Tob Control 1994; 3: 242–7CrossRefGoogle Scholar
  4. 4.
    U.S. Department of Health and Human Services. Reducing the health consequences of smoking: a report of the Surgeon General. Washington DC: U.S. Government Printing Office, 1989Google Scholar
  5. 5.
    Cavelaars AEJM, Kunst AE, Geurts JJM, et al. Educational differences in smoking: international comparison. BMJ 2000; 320: 1102–7PubMedCrossRefGoogle Scholar
  6. 6.
    Grunberg NE, Winders SE, Wewers ME. Gender differences in tobacco use. Health Psychol 1991; 10: 143–53PubMedCrossRefGoogle Scholar
  7. 7.
    Fiore MC. Trends in cigarette smoking in the United States. Med Clin North Am 1992; 76: 289–303PubMedGoogle Scholar
  8. 8.
    Wald NJ, Hacksaw AK. Cigarette smoking: an epidemiological overview. Br Med Bull 1996; 52: 3–11PubMedCrossRefGoogle Scholar
  9. 9.
    Ernster VL, Grady D, Miike R, et al. Facial wrinkling in men and women, by smoking status. Amer J Publ Health 1995; 85: 78–82CrossRefGoogle Scholar
  10. 10.
    Sacks JJ, Nelson DE. Smoking and injuries: an overview. Prev Med 1994; 23: 515–20PubMedCrossRefGoogle Scholar
  11. 11.
    Prescott E, Hippe M, Schnohr P, et al. Smoking and risk of myocardial infarction in women and men: longitudinal population study. BMJ 1998; 316: 1043–7PubMedCrossRefGoogle Scholar
  12. 12.
    Baron JA, La Vecchia C, Levi F. The anti-estrogenic effect of cigarette smoking in women. Am J Obstet Gynecol 1990; 162: 502–14PubMedGoogle Scholar
  13. 13.
    Zang EA, Wynder EL. Differences in lung cancer risk between men and women: examination of the evidence. J Natl Cancer Inst 1996; 88: 183–92PubMedGoogle Scholar
  14. 14.
    Risch HA, Howe GR, Jain M, et al. Are female smokers at higher risk for lung cancer than male smokers: a case-control analysis by histologic type. Am J Epidemiol 1993; 138: 281–93PubMedGoogle Scholar
  15. 15.
    Prescott E, Osier M, Hein HO, et al. Gender and smoking-related risk of lung cancer. Epidemiology 1998; 9: 79–83PubMedCrossRefGoogle Scholar
  16. 16.
    Osann KE, Anton Culver H, Kurosaki T, et al. Gender differences in lung cancer risk associated with cigarette smoking. Int J Cancer 1993; 54: 44–8PubMedCrossRefGoogle Scholar
  17. 17.
    Siegfried JM, Davis ALG, Gupta C. Role of estrogens in non-small cell lung cancer [abstract]. Proc Am Assoc Cancer Res 2000; 41: 138Google Scholar
  18. 18.
    Mollerup S, Ryberg D, Hewer A, et al. Sex differences in lung CYP1A1 expression and DNA adduct levels among lung cancer patients. Cancer Res 1999; 59: 3317–20PubMedGoogle Scholar
  19. 19.
    Xu X, Li B, Wang L. Gender difference in smoking effects on adult pulmonary function. Eur Respir J 1994; 7: 477–83PubMedCrossRefGoogle Scholar
  20. 20.
    Prescott E, Bjerg AM, Andersen PK, et al. Gender difference in smoking effects on lung function and risk of hospitalization for COPD: results from a Danish longitudinal population study. Eur Respir J 1997; 10:822–7PubMedGoogle Scholar
  21. 21.
    Morabia A, Berstein M, Heritier S, et al. Relation of breast cancer with passive and active exposure to tobacco smoke. Am J Epidemiol 1996; 143: 918–28PubMedCrossRefGoogle Scholar
  22. 22.
    Hornsby PP, Wilcox AJ, Weinberg CR. Cigarette smoking and disturbance of menstrual function. Epidemiology 1998; 9: 193–8PubMedCrossRefGoogle Scholar
  23. 23.
    Hughes EG, Brennan BG. Does cigarette smoking impair natural or assisted fecundity? Fertil Steril 1996; 66: 679–89PubMedGoogle Scholar
  24. 24.
    McKinlay SM, Bifano NL, McKinlay JB. Smoking and age at menopause in women. Ann Intern Med 1985; 103: 350–6PubMedGoogle Scholar
  25. 25.
    Haglund B, Cnattingius S. Cigarette smoking as a risk factor for sudden infant death syndrome: a population-based study. Am J Pub Health 1990; 80: 29–32CrossRefGoogle Scholar
  26. 26.
    Blake SV, Gurrin LC, Evans SF, et al. Maternal cigarette smoking during pregnancy, low birth weight, and subsequent blood pressure in early childhood. Early Hum Dev 2000; 57: 137–47PubMedCrossRefGoogle Scholar
  27. 27.
    Olds DL, Henderson CR, Tatelbaum R. Intellectual impairment in children of women who smoke cigarettes during pregnancy. Pediatrics 1994; 93: 221–7PubMedGoogle Scholar
  28. 28.
    Orlebecke JF, Knol DL, Verhulst FC. Child behavior problems increased by maternal smoking during pregnancy. Arch Environ Health 1999; 54: 15–9CrossRefGoogle Scholar
  29. 29.
    Kandel DB, Wu P, Davies M. Maternal smoking during pregnancy and smoking by adolescent daughters. Am J Pub Health 1994; 84: 1407–13CrossRefGoogle Scholar
  30. 30.
    Oncken CA. Toxicity and physiologic effects of nicotine during pregnancy. Presented at the Alternative Nicotine Delivery Systems Conference; 1997 Mar 21–23; TorontoGoogle Scholar
  31. 31.
    Rosenberg L, Palmer JR, Shapiro S. Decline in the risk of myocardial infarction among women who stop smoking. N Engl JMed 1990; 322: 213–7CrossRefGoogle Scholar
  32. 32.
    Wilson K, Gibson N, Williams A, et al. Effect of smoking cessation on mortality after myocardial infarction. Arch Intern Med 2000; 160: 939–44PubMedCrossRefGoogle Scholar
  33. 33.
    Kawachi I, Colditz GA, Stampfer MJ, et al. Smoking cessation and decreased risk of stroke in women. JAMA 1993; 269: 232–6PubMedCrossRefGoogle Scholar
  34. 34.
    Ockene JK. Smoking among women across the lifespan: prevalence, interventions, and implications for cessation research. Ann Behav Med 1993; 15: 135–48Google Scholar
  35. 35.
    Swan GE, Ward MN, Carmelli D, et al. Differential rates of relapse in subgroups of male and female smokers. J Clin Epidemiol 1993; 46: 1041–53PubMedCrossRefGoogle Scholar
  36. 36.
    Fortmann SP, Killen JD. Who shall quit? Comparison of volunteer and population-based recruitment in two minimal-contact smoking cessation studies. Am J Epidemiol 1994; 140: 39–51PubMedGoogle Scholar
  37. 37.
    Kabat GC, Wynder EL. Determinants of quitting smoking. Am J Publ Health 1987; 77: 1301–5CrossRefGoogle Scholar
  38. 38.
    Ward KD, Klesges RC, Zbikowski SM, et al. Gender differences in the outcome of an unaided smoking cessation attempt. Addict Behav 1997; 22: 521–33PubMedCrossRefGoogle Scholar
  39. 39.
    Bjornson W, Rand C, Connett JE, et al. Gender differences in smoking cessation after 3 years in the Lung Health Study. Am J Pub Health 1995; 85: 223–30CrossRefGoogle Scholar
  40. 40.
    Gourlay SG, Forbes A, Marriner T, et al. Prospective study of factors predicting outcome of transdermal nicotine treatment in smoking cessation. BMJ 1994; 309: 842–6PubMedCrossRefGoogle Scholar
  41. 41.
    Royce JM, Corbett K, Sorensen G, et al. Gender, social pressure, and smoking cessation: the community intervention trial for smoking cessation (COMMIT) at baseline. Soc Sci Med 1997; 44: 359–70PubMedCrossRefGoogle Scholar
  42. 42.
    Senore C, Battista RN, Shapiro SH, et al. Predictors of smoking cessation following physicians’ counseling. Prev Med 1998; 27: 412–21PubMedCrossRefGoogle Scholar
  43. 43.
    Wetter D, Kenford SL, Smith SS, et al. Gender differences in smoking cessation. J Consult Clin Psychol 1999; 67: 555–62PubMedCrossRefGoogle Scholar
  44. 44.
    Centers for Disease Control. Surveillance for selected tobacco-use behaviors — United States, 1900–1994. Morbid Mortal Wkly Rep 1994; 43: 1–43Google Scholar
  45. 45.
    Burt RD, Peterson AV. Smoking cessation among high school seniors. Prev Med 1998; 27: 319–27PubMedCrossRefGoogle Scholar
  46. 46.
    Patton GC, Carlin JB, Coffey C, et al. The course of early smoking: a population-based cohort study over three years. Addict 1998; 93: 1251–60CrossRefGoogle Scholar
  47. 47.
    Sussman S, Dent CW, Severson H, et al. Self-initiated quitting among adolescent smokers. Prev Med 1998; 27 Suppl.: A19–A28PubMedCrossRefGoogle Scholar
  48. 48.
    Gritz ER, Thompson B, Emmons K, et al. Gender differences among smokers and quitters in the Working Well Trial. Prev Med 1998; 27: 553–61PubMedCrossRefGoogle Scholar
  49. 49.
    Whitlock EP, Vogt TM, Hollis JF, et al. Does gender affect response to a brief clinic-based smoking intervention? Am J Prev Med 1997; 13: 159–66PubMedGoogle Scholar
  50. 50.
    U.S. Department of Health and Human Services. The health consequences of smoking: nicotine addiction. Washington, DC: U.S. Government Printing Office, 1988Google Scholar
  51. 51.
    Svikis DS, Hatsukami DK, Hughes JR, et al. Sex differences in the tobacco withdrawal syndrome. Addict Behav 1986; 11: 459–62PubMedCrossRefGoogle Scholar
  52. 52.
    Pomerleau CS. Smoking and nicotine replacement treatment issues specific to women. Am J Health Behav 1996; 20: 291–9Google Scholar
  53. 53.
    Pomerleau CS, Tate JC, Lumley MA, et al. Gender differences in prospectively versus retrospectively assessed smoking withdrawal symptoms. J Subst Abuse 1994; 6: 433–40PubMedCrossRefGoogle Scholar
  54. 54.
    Zhu S, Melcer T, Sun J, et al. Smoking cessation with and without assistance: a population-based analysis. Am J Prev Med 2000; 18:305–11PubMedCrossRefGoogle Scholar
  55. 55.
    Blake SM, Klepp K-I, Pechacek TF, et al. Differences in smoking cessation strategies between men and women. Addict Behav 1989; 14:409–18PubMedCrossRefGoogle Scholar
  56. 56.
    Rogers LQ, Johnson KC, Young ZM, et al. Demographic bias in physician smoking cessation counseling. Am J Med Sci 1997; 313: 153–8PubMedCrossRefGoogle Scholar
  57. 57.
    Young JM, Ward JE. Influence of physician and patient gender on provision of smoking cessation advice in general practice. Tob Control 1998; 7: 360–3PubMedCrossRefGoogle Scholar
  58. 58.
    Woolverton WL, Nader MA. Experimental evaluation of the reinforcing effects of drugs. In: Adler M, Cowan A, editors. Modern methods in pharmacology. Vol. 6. New York: Wiley-Liss, Inc., 1992: 165–92Google Scholar
  59. 59.
    Shiffman S, Gnys M, Richards TJ, et al. Temptations to smoke after quitting: a comparison of lapsers and maintainers. Health Psychol 1996; 15: 455–61PubMedCrossRefGoogle Scholar
  60. 60.
    Killen JD, Fortmann SP, Newman B, et al. Evaluation of a treatment approach combining nicotine gum with self-guided behavioral treatments for smoking relapse prevention. J Consult Clin Psychol 1990; 58: 85–92PubMedCrossRefGoogle Scholar
  61. 61.
    Perkins KA, Donny E, Caggiula AR. Sex differences in nicotine effects and self-administration: human and animal evidence. Nicotine Tob Res 1999; 1: 301–5PubMedCrossRefGoogle Scholar
  62. 62.
    Perkins KA, Gerlach D, Vender J, et al. Sex differences in the subjective and reinforcing effects of visual and olfactory cigarette smoke stimuli. Nicotine Tob Res. In pressGoogle Scholar
  63. 63.
    Robbins SJ, Ehrman RN, Childress AR, et al. Comparing levels of cocaine cue reactivity in male and female outpatients. Drug Alcohol Depend 1999; 53: 223–30PubMedCrossRefGoogle Scholar
  64. 64.
    Sofuoglu M, Dudish-Poulsen S, Nelson D, et al. Gender differences in the subjective effects from multiple deliveries of smoked cocaine in humans. Exp Clin Psychopharmacol 1999; 7: 274–83PubMedCrossRefGoogle Scholar
  65. 65.
    Fagerstrom K-O. Effects of nicotine chewing gum and follow-up appointments in physician-based smoking cessation. Prev Med 1984; 13: 517–27PubMedCrossRefGoogle Scholar
  66. 66.
    Murray RP, Voelker HT, Rakos RF, et al. Intervention for relapse to smoking: the Lung Health Study Restart Programs. Addict Behav 1997; 22: 281–6PubMedCrossRefGoogle Scholar
  67. 67.
    Sachs DPL, Sawe U, Leischow SJ. Effectiveness of a 16-hour transdermal nicotine patch in a medical practice setting, with-out intensive group counseling. Arch Intern Med 1993; 153: 1881–90PubMedCrossRefGoogle Scholar
  68. 68.
    Davis LJ, Hurt RD, Offord KP, et al. Self-administered nicotine-dependence scale (SANDS): item selection, reliability estimation, and initial validation. J Clin Psychol 1994; 50: 918–30PubMedCrossRefGoogle Scholar
  69. 69.
    Swan GE, Jack LM, Ward MM. Subgroups of smokers with different success rates after use of transdermal nicotine. Addict 1997; 92: 207–18CrossRefGoogle Scholar
  70. 70.
    Russell MAH, Stapleton JA, Feyerabend C, et al. Targeting heavy smokers in general practice: randomised controlled trial oftransdermal nicotine patches. BMJ 1993;306: 1308–12PubMedCrossRefGoogle Scholar
  71. 71.
    Jorenby DE, Smith SS, Fiore MC, et al. Varying nicotine patch dose and type of smoking cessation counseling. JAMA 1995; 274: 1347–52PubMedCrossRefGoogle Scholar
  72. 72.
    Sonderskov J, Olsen J, Sabroe S, et al. Nicotine patches in smoking cessation: a randomized trial among over-the-counter customers in Denmark. Am J Epidemiol 1997; 145: 309–18PubMedCrossRefGoogle Scholar
  73. 73.
    Blondal T. Controlled trial of nicotine polacrilex gum with supportive measures. Arch Intern Med 1989; 149: 1818–21PubMedCrossRefGoogle Scholar
  74. 74.
    Fortmann SP, Killen JD. Nicotine gum and self-help behavioral treatment for smoking relapse prevention: results from a trial using population-based recruitment. J Consult Clin Psychol 1995; 63: 460–8PubMedCrossRefGoogle Scholar
  75. 75.
    Hjalmarson A, Nilsson F, Sjostrom L, et al. The nicotine inhaler in smoking cessation. Arch Intern Med 1997; 157: 1721–8PubMedCrossRefGoogle Scholar
  76. 76.
    Jackson PH, Stapleton JA, Russell MAH, et al. Predictors of outcome in a general practitioner intervention against smoking. Prevent Med 1986; 15: 244–53CrossRefGoogle Scholar
  77. 77.
    Glover ED, Sachs DPL, Stitzer ML, et al. Smoking cessation in highly dependent smokers with 4 mg nicotine polacrilex. Am J Health Behav 1996; 20: 319–32Google Scholar
  78. 78.
    Norregaard J, Tonnesen P, Petersen L. Predictors and reasons for relapse in smoking cessation with nicotine and placebo patches. Prev Med 1993; 22: 261–71PubMedCrossRefGoogle Scholar
  79. 79.
    Stapleton JA, Russell MAH, Feyerabend C, et al. Dose effects and predictors of outcome in a randomized trial of transdermal nicotine patches in general practice. Addiction 1995; 90: 31–42PubMedCrossRefGoogle Scholar
  80. 80.
    West R, Hajek P, Nilsson F, et al. Individual differences in preferences for and responses to four nicotine replacement products. Psychopharmacology 2001; 15: 225–30CrossRefGoogle Scholar
  81. 81.
    Perkins KA. Sex differences in nicotine versus non-nicotine reinforcement as determinants of tobacco smoking. Exp Clin Psychopharmacol 1996; 4: 166–77CrossRefGoogle Scholar
  82. 82.
    Gariti P, Alterman AI, Barber W, et al. Cotinine replacement levels for a 21 mg/day transdermal nicotine patch in an outpatient treatment setting. Drug Alcohol Depend 1999; 54: 111–6PubMedCrossRefGoogle Scholar
  83. 83.
    Gourlay SG, Forbes A, Marriner T, et al. Predictors and timing of adverse experiences during transdermal nicotine therapy. Drug Saf 1999; 20: 545–55PubMedCrossRefGoogle Scholar
  84. 84.
    Perkins KA. Nicotine discrimination in men and women. Pharmacol Biochem Behav 1999; 64: 295–9PubMedCrossRefGoogle Scholar
  85. 85.
    Hatsukami D, Skoog K, Allen S, et al. Gender and the effects of different doses of nicotine gum on tobacco withdrawal symptoms. Exp Clin Psychopharmacol 1995; 3: 163–73CrossRefGoogle Scholar
  86. 86.
    Wetter D, Fiore MC, Young TB, et al. Gender differences in response to nicotine replacement therapy: objective and subjective indices of tobacco withdrawal. Exp Clin Psychopharmacol 1999; 7: 135–44PubMedCrossRefGoogle Scholar
  87. 87.
    Slemmer JE, Martin BR, Damaj MI. Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 2000; 295: 321–7PubMedGoogle Scholar
  88. 88.
    Hurt RD, Sachs DPL, Glover ED, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 1997; 337: 1195–202PubMedCrossRefGoogle Scholar
  89. 89.
    Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999; 340: 685–91PubMedCrossRefGoogle Scholar
  90. 90.
    Lerman C, Audrain J, Crystal S, et al. Gender differences in response to bupropion for smoking cessation [abstract]. Proceedings of the 7th Annual Meeting of the Society for Research on Nicotine and Tobacco; 2001 Mar 23–25; Seattle (WA)Google Scholar
  91. 91.
    Rose JE, Behm FM, Westman EC. Brand-switching and gender effects in mecamylamine/nicotine smoking cessation treatment [abstract]. Proceedings of the 5th Annual Meeting of the Society for Research on Nicotine and Tobacco; 1999 Mar 5–7; San Diego (CA)Google Scholar
  92. 92.
    Gourlay S, Benowitz NL. Is clonidine an effective smoking cessation therapy? Drugs 1995; 50: 197–207PubMedCrossRefGoogle Scholar
  93. 93.
    Glassman AH, Stetner F, Walsh BT, et al. Heavy smokers, smoking cessation, and clonidine. JAMA 1988; 259: 2863–6PubMedCrossRefGoogle Scholar
  94. 94.
    Franks P, Harp J, Bell B.Randomized, controlled trial of clonidine for smoking cessation in a primary care setting. JAMA 1989; 262; 3011–3PubMedCrossRefGoogle Scholar
  95. 95.
    Villagra VG, Rosenberger JL, Girolami S. Transdermal clonidine for smoking cessation: a randomized, double-blind, placebo controlled trial [abstract]. Circulation 1989; 80Suppl. 11:58Google Scholar
  96. 96.
    Prochazka AV, Petty TL, Nett L, et al. Transdermal clonidine reduced some withdrawal symptoms but did not increase smoking cessation. Arch Intern Med 1992; 152: 2065–9PubMedCrossRefGoogle Scholar
  97. 97.
    Glassman AH, Covey LS, Dalack GW, et al. Smoking cessation, clonidine, and vulnerability to nicotine among dependent smokers. Clin Pharmacol Ther 1993; 54: 670–9PubMedCrossRefGoogle Scholar
  98. 98.
    Hilleman DE, Mohiuddin SM, Delcore MG, et al. Randomized, controlled trial of transdermal clonidine for smoking cessation. Ann Pharmacother 1993; 27: 1025–8PubMedGoogle Scholar
  99. 99.
    Hall SM, Reus VI, Munoz RF, et al. Nortriptyline and cognitive-behavioral therapy in the treatment of cigarette smoking. Arch Gen Psychiatry 1998; 55: 683–90PubMedCrossRefGoogle Scholar
  100. 100.
    Covey LS, Glassman AH, Stetner F. Naltrexone effects on short-term and long-term smoking cessation. J Addict Dis 1999; 18: 31–40PubMedCrossRefGoogle Scholar
  101. 101.
    Covey LS, Glassman AH. A meta-analysis of double-blind placebo-controlled trials of clonidine for smoking cessation. Br J Addict 1991; 86: 991–8PubMedCrossRefGoogle Scholar
  102. 102.
    Gourlay S, Forbes A, Marriner T, et al. A placebo-controlled study of three clonidine doses for smoking cessation. Clin Pharmacol Ther 1994; 55: 64–9PubMedCrossRefGoogle Scholar
  103. 103.
    Pohl R, Yeragani, VK, Balon R, et al. Smoking in patients with panic disorder. Psychiatry Res 1992; 43: 253–62PubMedCrossRefGoogle Scholar
  104. 104.
    Cinciripini PM, Lapitsky L, Seay S, et al. A placebo-controlled evaluation of the effects of buspirone on smoking cessation: differences between high- and low-anxiety smokers. J Clin Psychopharmacol 1995; 15: 182–91PubMedCrossRefGoogle Scholar
  105. 105.
    Borland R. Slip-ups and relapse in attempts to quit smoking. Addict Behav 1990; 15: 235–45PubMedCrossRefGoogle Scholar
  106. 106.
    Blondal T, Gudmundsson LJ, Tomasson K, et al. The effects of fluoxetine combined with nicotine inhalers in smoking cessation: a randomized trial. Addict 1999; 94: 1007–15CrossRefGoogle Scholar
  107. 107.
    Hitsman B, Pingitore R, Spring B, et al. Antidepressant pharmacotherapy helps some cigarette smokers more than others. J Consult Clin Psychol 1999; 67: 547–54PubMedCrossRefGoogle Scholar
  108. 108.
    Berlin I, Said S, Spreuxvaroquaux O, et al. A reversible monoamine-oxidase-A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers. Clin Pharmacol Ther 1995; 58: 444–52PubMedCrossRefGoogle Scholar
  109. 109.
    Almeida LEF, Pereira EFR, Alkondon M, et al. The opioid antagonist naltrexone inhibits activity and alters expression of alpha 7 and alpha 4/beta 2 nicotinic receptors in hippocampal neurons: implications for smoking cessation programs. Neuropharmacol 2000; 39: 2740–55CrossRefGoogle Scholar
  110. 110.
    Hutchison KE, Monti PM, Rohsenow DJ, et al. Effects of naltrexone with nicotine replacement on smoking cue reactivity: preliminary results. Psychopharmacol 1999; 142: 139–43CrossRefGoogle Scholar
  111. 111.
    Pirie PL, Murray DM, Luepker RV. Smoking and quitting in a cohort of young adults. Am J Pub Health 1991; 81: 324–7CrossRefGoogle Scholar
  112. 112.
    Nides M, Rand C, Dolce J, et al. Weight gain as a function of smoking cessation and 2-mg nicotine gum use among middle-aged smokers with mild lung impairment in the first 2 years of the Lung Health Study. Health Psychol 1994; 13: 354–61PubMedCrossRefGoogle Scholar
  113. 113.
    Weekley CK, Klesges RC, Relyea G. Smoking as a weight-control strategy and its relationship to smoking status. Addict Behav 1992; 17:259–71PubMedCrossRefGoogle Scholar
  114. 114.
    Pinto BM, Borrelli B, King TK, et al. Weight control smoking among sedentary women. Addict Behav 1999; 24: 75–86PubMedCrossRefGoogle Scholar
  115. 115.
    Meyers AW, Klesges RC, Winders SE, et al. Are weight concerns predictive of smoking cessation? A prospective analysis. J Consult Clin Psychol 1997; 66: 448–52Google Scholar
  116. 116.
    Mizes JS, Sloan DM, Segraves K, et al. The influence of weight-related variables on smoking cessation. Behav Ther 1998; 29: 371–85CrossRefGoogle Scholar
  117. 117.
    Perkins KA, Levine M, Marcus MD, et al. Addressing women’s concerns about weight gain due to smoking cessation. J Subst Abuse Treat 1997; 14: 1–10CrossRefGoogle Scholar
  118. 118.
    Doherty K, Militello FS, Kinnunen T, et al. Nicotine gum dose and weight gain after smoking cessation. J Consult Clin Psychol 1996; 64: 799–807PubMedCrossRefGoogle Scholar
  119. 119.
    Jorenby DE, Hatsukami DK, Smith SS, et al. Characterization of tobacco withdrawal symptoms: transdermal nicotine reduces hunger and weight gain. Psychopharmacology 1996; 128: 130–8PubMedCrossRefGoogle Scholar
  120. 120.
    Rigotti NA, Thorndike AN, Durcan MJ, et al. Post-cessation weight gain in smokers taking bupropion: the effect of gender [abstract]. Proceedings of the 6th Annual Meeting of the Society for Research on Nicotine and Tobacco; 2000 Feb 18–20; Arlington (VA)Google Scholar
  121. 121.
    Spring B, Wurtman J, Wurtman R, et al. Efficacies of dex-fenfluramine and fluoxetine in preventing weight gain after smoking cessation. Am J Clin Nutr 1995; 62: 1181–7PubMedGoogle Scholar
  122. 122.
    Hall SM, Tunstall CD, Vila KL, et al. Weight gain prevention and smoking cessation: cautionary findings. Am J Pub Health 1992; 82: 799–803CrossRefGoogle Scholar
  123. 123.
    Pirie PL, McBride CM, Hellerstedt W, et al. Smoking cessation in women concerned about weight. Am J Pub Health 1992; 82: 1238–43CrossRefGoogle Scholar
  124. 124.
    Marcus BH, Albrecht AE, King TK, et al. The efficacy of exercise as an aid for smoking cessation in women. Arch Intern Med 1999; 159: 1229–34PubMedCrossRefGoogle Scholar
  125. 125.
    Perkins KA, Marcus MD, Levine MD, et al. Cognitive-behavioral therapy to reduce weight concerns improves smoking cessation outcome in weight-concerned women. J Consult Clin Psychol. In pressGoogle Scholar
  126. 126.
    Mielke MM, Jorenby DE, Fiore MC. Achieving smoking cessation in nicotine-dependent individuals. CNS Drugs 1997; 8: 12–20CrossRefGoogle Scholar
  127. 127.
    Benowitz NL. Nicotine replacement therapy during pregnancy. JAMA 1991; 266: 3174–7PubMedCrossRefGoogle Scholar
  128. 128.
    Wright LN, Thorp JM, Kuller JA, et al. Trandermal nicotine replacement in pregnancy: maternal pharmacokinetics and fetal effects. Am J Obstet Gynecol 1997; 176: 1090–4PubMedCrossRefGoogle Scholar
  129. 129.
    O’Hara P, Portser SA, Anderson BP. The influence of menstrual cycle changes on the tobacco withdrawal syndrome in women. Addict Behav 1989; 14: 595–600PubMedCrossRefGoogle Scholar
  130. 130.
    Perkins KA, Levine M, Marcus M, et al. Menstrual cycle phase and tobacco withdrawal after quitting smoking. J Consult Clin Psychol 2000; 68: 176–80PubMedCrossRefGoogle Scholar
  131. 131.
    Burger J, Gochfeld M. Gender differences in smoking behavior in a university workplace. Sex Roles 1989; 20: 523–33CrossRefGoogle Scholar
  132. 132.
    Murray RP, Johnston JJ, Dolce JJ, et al. Social support for smoking cessation and abstinence: the Lung Health study. Addict Behav 1995; 20: 159–70PubMedCrossRefGoogle Scholar
  133. 133.
    Sidney S, Tekawa I, Friedman G. Mentholated cigarette use among multiphasic examinees, 1979–86. Am J Pub Health 1989; 79: 1415–6CrossRefGoogle Scholar
  134. 134.
    Parrott AC, Craig D. Psychological functions served by nicotine chewing gum. Addict Behav 1995; 20: 271–8PubMedCrossRefGoogle Scholar
  135. 135.
    Shiffman S. Smoking cessation treatment: any progress? J Consult Clin Psychol 1993; 61: 718–22PubMedCrossRefGoogle Scholar
  136. 136.
    Perkins KA, Hickox M, Grobe JE. Behavioral economics of smoking. In: Bickel W, Vuchinich R, editors. Refraining health behavior change with behavioral economics. Mahwah (NJ): Erlbaum, 2000: 265–92Google Scholar
  137. 137.
    Niaura R, Shadel WG, Abrams DB, et al. Individual differences in cue reactivity among smokers trying to quit: effects of gender and cue type. Addict Behav 1998; 23: 209–24PubMedCrossRefGoogle Scholar
  138. 138.
    Grobe JE, Perkins KA. tobacco intake [abstract]. Proceedings of the 6th Annual Meeting of the Society for Research on Nicotine and Tobacco; 2000 Feb 18–20; Arlington (VA)Google Scholar
  139. 139.
    Cinciripini PM, Lapitsky L, Seay S, et al. The effects of smoking schedules on cessation outcome: can we improve on common methods of gradual and abrupt nicotine withdrawal? J Consult Clin Psychol 1995; 63: 388–99PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2001

Authors and Affiliations

  1. 1.Department of Psychiatry, Western Psychiatric Institute and ClinicUniversity of Pittsburgh School of MedicinePittsburghUSA

Personalised recommendations